70.0 B

GHK-Cu

Also known as: Copper peptide, GHK-copper

Strong Clinical Evidence Category 2 Restricted
Research Evidence 90.0/100
Safety Profile 50.0/100

36 Clinical Trials

Unknown: 2 PHASE4: 5 PHASE3: 4 PHASE2, PHASE3: 1 PHASE2: 9 PHASE1, PHASE2: 4 PHASE1: 3 NA: 7 EARLY_PHASE1: 1

Showing 5 of 36 trials.

18 Research Papers

Showing 5 of 18 papers by citation count.

FDA Data

Not FDA-Approved

GHK-Cu has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.

This peptide is classified as FDA Category 2 — it is prohibited from use in compounding pharmacies effective 2024. Obtaining it requires unregulated sources.

Frequently Asked Questions

Is GHK-Cu FDA approved?
No, GHK-Cu is not FDA approved. It is classified as FDA Category 2 and is banned from compounding pharmacies.
How many clinical trials has GHK-Cu been studied in?
GHK-Cu has been studied in 36 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for GHK-Cu?
GHK-Cu has a CheckPeptides trust score of 70.0/100 (grade: B). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026

Quick Facts

Classification
Copper-binding tripeptide
Molecular Weight
400.9 Da
Regulatory Status
N/A

Score Breakdown

Research Evidence 90.0/100
Safety Profile 50.0/100

Evidence Summary

Clinical Trials
36
Research Papers
18
Trust Score
70.0/100
Grade
B

Compare Peptides

See how GHK-Cu stacks up against similar peptides.

View Comparisons
← Browse all peptides